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Decreased levels of matrix metalloproteinases (MMPs) or excess levels of their tissue inhibitors (TIMPs) may contribute to
dysregulation of extracellular matrix turnover in systemic sclerosis (SSc). In a cross-sectional study of 106 SSc patients, we
measured serum levels of TIMP-4 which is preferentially expressed in cardiovascular structures and searched for correlations
with simultaneously performed echocardiography measurements of pulmonary artery systolic pressure (PASP), myocardial
performance, and pulmonary function tests. TIMP-4, but not MMP-9, levels were signiﬁcantly raised in patients with SSc
than controls. However, in the subgroup of patients with PASP measurements lower to 40mmHg (n = 69), TIMP-4 levels
were comparable to controls irrespective of the presence of diﬀuse or limited skin involvement, or lung ﬁbrosis. Individual
PASP measurements suggestive of pulmonary hypertension were associated with increased TIMP-4 serum levels (P = .03),
independently of age, extent of skin sclerosis, or lung ﬁbrosis, suggesting a cardiopulmonary vasculature-speciﬁc role of TIMP-4
activation in SSc.
Copyright © 2008 Elias J. Gialafos et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Systemic sclerosis (SSc) is characterized by excessive accu-
mulation of collagen and other components of extracellular
matrix in the skin and internal organs, being perhaps the
prototypic disorder of a generalized disruption of connec-
tive tissue homeostasis [1]. Vasoconstriction and structural
changes of the blood vessels, including intimal proliferation
and obstruction, are expressed clinically as Raynaud’s phe-
nomenon, digital ulcers, renal disease, cardiac disease, and
pulmonary hypertension (PH). Cardiopulmonary complica-
tions, including PH which occurs in a signiﬁcant proportion
of patients either as an isolated abnormality or secondary
to pulmonary ﬁbrosis, are currently the leading cause of
death in SSc [1, 2]. Although eﬀective screening for PH has
proven diﬃcult, many experts believe that early detection
and intervention may alter the natural history of the disease
[3].
Connective tissue turnover depends on the balance
between the synthesis and degradation of the extracellular
matrix. Extracellular matrix degradation is regulated mainly
by matrix metalloproteinases (MMP-1 to MMP-28) and an
important mechanism for the regulation of their activity
is via binding to a family of homologous proteins, the
tissue inhibitors of metalloproteinases (TIMP-1 to TIMP-
4). Several lines of evidence indicate that the balance
between MMPs and TIMPs levels governs connective tissue
homeostasis, being a crucial determinant in inﬂammation,
ﬁbrosis and angiogenesis [4, 5]. Fibroblasts derived from
patients with SSc produce increased amounts of TIMP-1,
TIMP-2, and TIMP-3 [6, 7], whereas expression of MMP-1,
MMP-2, and MMP-3 genes is decreased in ﬁbroblasts from2 Mediators of Inﬂammation
patients with early SSc compared to ﬁbroblasts from healthy
individuals or patients with late-stage disease [6]. These and
other results suggest that excess levels of TIMPs, or decreased
levels of MMPs may contribute to matrix accumulation in
SSc.
TIMP-4 is the newest member in the mammalian TIMP
family and diﬀers from the other 3 TIMPs by its expression
pattern. TIMP-4 is abundantly expressed in human cardio-
vascular structures, while all other tissues at the normal
state, including the lung parenchyma, are characterized by
low or absent expression [8]. Animal studies have suggested
an important role of TIMP-4 in inﬂammatory diseases
and cardiovascular pathologies [4, 5]. Moreover, TIMP-4
myocardial expression is remarkably increased in patients
with aortic stenosis undergoing surgery [9], and in dilated
cardiomyopathy patients with deteriorating heart failure
[10]. On the other hand, MMP-9 is also found in cardiac
myocytes, cardiac ﬁbroblasts, and endocardial cells [4].
Although among other TIMPs there is only little speciﬁcity
for inhibiting individual MMPs, key factors in every MMP
inhibition are the size, charge, and polarity of residue 2 in
the particular structure of TIMP-4 [11].
Based on the above, we hypothesized that aberrant
TIMP-4 and/or MMP-9 activation may play a role in
cardiovascular complications of SSc. To test this hypothesis,
we examined serum levels of these molecules as well as of
B-type natriuretic peptide (BNP), an established marker of
SSc-related cardiovascular pathology [1, 12], and searched
for correlations with echocardiography measurements of
pulmonary artery systolic pressure (PASP), myocardial per-
formance, and pulmonary function tests.
2. PATIENTS AND METHODS
2.1. Studypopulation
Onehundred and six consecutivepatients (102 women)with
SSc, aged between 22 and 80 years (mean 54 ± 13 years)
and with disease duration ranging between 2 to 25 years
(mean 11 ± 4 years) from date of the ﬁrst non-Raynaud’s
phenomenon SSc manifestation, participated in this cross-
sectional study. Blood samples were collected at the day of
their regular follow-up which included lung function tests
and echocardiography. SSc patients with previous myocar-
dial infarction or stroke, valvular or congenital heart disease,
hypertrophic cardiomyopathy, previous history of arterial
hypertension, chronic obstructive pulmonary disease, or
malignancies, as well those patients receiving bosentan or
intravenous iloprost during the last 4 weeks, were excluded.
Seventeen patients (15%) were current smokers. As shown
in Table 1, medications included calcium-channel blockers
in 77%, angiotensin-converting enzyme inhibitors in 55%,
corticosteroids in 29%, cyclophosphamide in 22%, and
mycophenolate mofetil in 7% of patients.
Pulmonary function tests (Master-Screen Diﬀusion,
Jaeger, Wuerzburg, Germany) included spirometry, total
lung capacity (TLC), and carbon monoxide diﬀusing capac-
ity (DLCO) measurements, as described in [13, 14]. In all
patients with both TLC and DLCO lower than 80% of
predicted (indicative of pulmonary ﬁbrosis) high resolution
computed tomography of the lung [14] performed during
the previous 6 months had conﬁrmed the presence of
ﬁbrosis.
Complete echocardiographic examination (Hewlet-
Packard Sonos 1000 ultrasound system, using a 2.5MHz
transducer) was performed as described in detail elsewhere
[15], and established indices of myocardial performance
for right and left ventricles (Tei-index) were calculated,
as described in [16]. PASP was considered elevated when
exceeded the level of 40mmHg [17]. There were 37 patients
with elevated PASP; 18 of them had undergone right heart
catheterization during the previous year conﬁrming the
presence of PH secondary to SSc [18]i na l l .
Sera collected from 24 age-matched healthy subjects
(54 ± 19 years, 23 women), who fulﬁlled the exclusion
criteriaemployedforpatients,servedascontrols.Allcontrols
underwent a complete examination comprising electrocar-
diogram, echocardiography and exercise stress to exclude
asymptomatic cardiac disease. Of the 24 control subjects, 8
women were current smokers, a marginally higher frequency
comparing to 17 of 106 patients with SSc (P = .052) .
The study protocol was approved by Laikon Hospital and
Alexandra Hospital ethics committees and all subjects gave
informed consent.
2.2. MeasurementsofcirculatingTIMP-4,MMP-9,
andBNPmolecules
Circulating levels of TIMP-4 and MMP-9were measured
by quantitative sandwich enzyme-linked immunosorbent
assays (Quantikine human TIMP-4 and Quantikine human
MMP-9 total, respectively, R&D Systems Inc., Minneapolis,
Minn, USA) according to the manufacturer’s instructions in
patient’s and control sera that had been kept at −70C. BNP
concentrations were measured immediately after venipunc-
ture in plasma samples from SSc patients using a sand-
wich immunoenzymatic assay (Triage BNP test, Biosite,
San Diego, Calif, USA), according to the manufacturer’s
instructions.
2.3. Statisticalanalysis
Comparisons for continuous variables between groups were
performed using t-test or Mann-Whitney test, in case of
normal or skewed distribution, respectively. Age-adjusted
partial correlation coeﬃcients were built to evaluate exam-
ined correlations. TIMP-4, MMP-9/TIMP-4 ratios, and BNP
were expressed as log10(TIMP-4), log10(MMP-9/TIMP-4),
and log10(BNP), respectively, when correlated or regressed
because of their skewed distribution. Bonferroni correction
was used in cases of multiple testing to avoid false positive
associations. Multivariate regression analysis was used to
assess the association of TIMP-4 and/or MMP-9 levels with
PASP, after controlling for possible confounders, such as age,
presence or not of lung ﬁbrosis, type of skin involvement
(diﬀuse or limited), and BNP. The statistical package used
w a sS P S S1 3 . 0 .V a l u e sa r ee x p r e s s e da sm e a n± SD and a P-
value < .05 was considered signiﬁcant.Elias J. Gialafos et al. 3
Table 1: Characteristics of patients with systemic sclerosis (SSc).
All patients Diﬀuse SSc Limited SSc
Women/men (n) 102/4 71/4 31/0
Mean age ± SD, 54 ± 13 52 ± 13 56 ± 12
years (range) (22–80) (22–80) (25–77)
Mean disease duration ± SD, 11 ± 41 0 ± 31 2 ± 4
years (range) (2–25) (2–20) (2–25)
Medications, % of patients (n)
Calcium—channel blockers 77% (82) 76% (57) 81% (25)
Angiotensin—converting enzyme inhibitors 55% (58) 63% (47) 31% (11)
Corticosteroids 29% (31) 35% (26) 16% (5)
Cyclophosphamide 22% (21) 23% (17) 13% (4)
Mycophenolate mofetil 7% (7) 8% (6) 3% (1)
Table 2: Pulmonary function tests (mean ± SD of % predicted,
number of patients with less than 80% of predicted) in patients with
systemic sclerosis (SSc).
All patients Diﬀuse SSc Limited SSc
(n = 106) (n = 75) (n = 31)
FEV1 86 ± 17, 32 86 ± 18, 26 88 ± 16, 6
FVC 87 ± 19, 31 87 ± 20, 25 90 ± 16, 6
TLC 80 ± 16, 46 79 ± 16, 34 81 ± 17, 12
DLCO 68 ± 21, 81 67 ± 22, 54 69 ± 19, 27
FEV1: forced expiratory volume at 1 second;
FVC: forced vital capacity;
TLC: total lung capacity;
DLCO: diﬀusing lung capacity for carbon monoxide.
3. RESULTS
3.1. CirculatingMMP-9andTIMP-4levelsandextent
ofskinorpulmonaryﬁbrosisinSSc
Ofthe106patients,75haddiﬀuse(truncalskininvolvement)
and 31 patients had limited SSc (skin sclerosis conﬁned to
hands, arms, feet, and face), according to LeRoy’s classiﬁca-
tion [19]( Table 1). Mean values of pulmonary function tests
were comparable between patients with diﬀuse and limited
SSc (Table 2); pulmonary ﬁbrosis was present in 46 patients
(34 with diﬀuse SSc).
MMP-9 levels were not diﬀerent between the whole SSc
patient group and controls (530 ± 260ng/mL versus 446 ±
201ng/mL, resp.), but patients with diﬀuse SSc had higher
MMP-9 levels than controls (Figure 1(a)) as well as than
patients with limited SSc (587 ± 266ng/mL versus 393 ±
182ng/mL, P = .0003). No signiﬁcant diﬀerence was noted
between patientswithlung ﬁbrosisandthose without(548 ±
222ng/mL versus 517 ± 287ng/mL).
In contrast to MMP-9, TIMP-4 levels were raised in
the whole SSc patient group (2035 ± 1064pg/mL, range
380–4961pg/mL) compared to controls (1484 ± 489pg/mL,
range 683–2661pg/mL) as well as in subgroups of patients
with diﬀuse (2028 ± 1100pg/mL, range 380–4961ng/mL)
or limited SSc (2050 ± 987ng/mL, range 694–4900ng/mL).
Also, TIMP-4 levels were signiﬁcantly higher in patients
with pulmonary ﬁbrosis (2157 ± 1068ng/mL, range 846–
4900ng/mL) than controls (Figure 1(b)).
As shown in Table 3, age-adjusted partial correlations
revealed no signiﬁcant associations between individual
serum levels of MMP-9, TIMP-4, or their ratio with
corresponding pulmonary function tests. No signiﬁcant
diﬀerences, either for TIMP-4 or for MMP-9 mean levels,
were noted between patients receiving, or not, angiotensin-
converting enzyme inhibitors, or between patients receiving
immunomodulatory drugs and the remaining patients.
3.2. ElevatedpulmonaryarterypressureinSScis
associatedwithincreasedTIMP-4levels
Thirty seven of 106 patients with SSc (21 with diﬀuse and 16
with limited SSc) had PASP measurements equal or higher
than 40mmHg in echocardiography (range 40–85mmHg,
mean ± SD 51 ± 12mmHg). Age, disease duration,
digital ulcers, arthritis, esophageal or intestinal involvement,
antibodies to Scl-70, and current treatment regimens were
comparable between patients with elevated PASP and the
remaining patients. Of patients with elevated PASP, 22 had
concomitant pulmonary ﬁbrosis; the remaining 15 patients,
all with limited SSc, had DLCO reduction as an isolated
abnormality.AsshowninTable 4,echocardiography-derived
measurements of myocardial performance were signiﬁcantly
compromised in patients with elevated PASP measurements
secondary to either diﬀuse or limited SSc, compared to
the remaining patients. High BNP blood levels reﬂecting
abnormalities in the cardiopulmonary vasculature were
found in many of the studied patients with SSc (depicted
in Figure 1(c)). As expected, BNP levels were increased
by almost 5-fold in patients with elevated PASP than the
remaining patients (Table 4).
As shown in Figure 2, TIMP-4 serum levels were
considerably higher in SSc patients with elevated PASP
measurements (2486 ± 1190pg/mL, range 850–4961pg/mL)
than the remaining patients (1792 ± 909pg/mL, range
380–4862pg/mL, P = .003). Notably, after excluding the
37 patients with PASP ≥40mmHg from the whole SSc
group, there were no signiﬁcant diﬀerences in TIMP-4
levels between the control group and patients with diﬀuse4 Mediators of Inﬂammation
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Figure 1: (a) MMP-9, (b) TIMP-4, and (c) BNP blood levels in SSc patients with diﬀuse (dSSc) and limited (lSSc) skin involvement as well
as in those patients with pulmonary ﬁbrosis (PF+) compared to healthy controls (Mann-Whitney test, NS denotes nonsigniﬁcant).
(1767 ± 929pg/mL, n = 53) or limited SSc (1875 ±
862pg/mL, n = 16), or patients with lung ﬁbrosis (1916 ±
918pg/mL, n = 24), or those without (1726 ± 908pg/mL,
n = 45). TIMP-4 levels diﬀered signiﬁcantly between SSc
patients, when as criterion for abnormally elevated PASP the
level of 50mmHg (2880 ± 1174pg/mL, n = 13, versus 1916
± 998pg/mL, P = .002), or the level of 45mmHg (2586 ±
1283pg/mL, n = 23 versus 1882 ± 948pg/mL, P = .02) was
considered.
In contrast, MMP-9 serum levels were slightly lower in
patientswithelevatedPASPthantheremainingpatients(511
± 265ng/mL and 541 ± 258ng/mL, resp.). MMP-9/TIMP-
4 ratios were signiﬁcantly smaller in patients with elevated
PASP (255 ± 192) than in those with PASP measurements
lower than 40mmHg (402 ± 380) (Figure 2).Elias J. Gialafos et al. 5
Table 3: Age-adjusted partial correlations (r) of MMP-9, TIMP-4 and their ratio with respiratory and cardiac indicators in 106 patients with
systemic sclerosis. Levels of signiﬁcance are shown in parentheses.
MMP-9 Log10(TIMP-4) Log10(MMP-9/TIMP-4)
Pulmonary function tests
FEV1 (%predicted) −0.14 (NS) −0.09 (NS) −0.04 (NS)
FVC (%predicted) −0.14 (NS) −0.14 (NS) −0.02 (NS)
TLC (%predicted) −0.16 (P = .070) −0.09 (NS) −0.09 (NS)
DLCO (%predicted) −0.19 (P = .068) −0.70 (NS) −0.11 (NS)
Cardiac parameters
PASP 0.02 (NS) 0.29 (P = 0.021) −0.15 (NS)
log10 (BNP) 0.00 (NS) 0.19 (NS) −0.15 (NS)
RV Tei Index 0.02 (NS) 0.15 (NS) −0.11 (NS)
LV Tei Index −0.23(P = .046) 0.17 (NS) −0.30 (P = 0.006)
LV EF (%) 0.07 (NS) −0.15 (NS) 0.15 (NS)
FEV1: forced expiratory volume at 1 second;
FVC: forced vital capacity;
TLC: total lung capacity;
DLCO: diﬀusing lung capacity for carbon monoxide;
PASP: pulmonary artery systolic pressure;
BNP: B-type natriuretic peptide;
RV: right ventricular;
LV: left ventricular;
EF: ejection fraction;
NS denotes nonsigniﬁcant.
Table 4: Echocardiography-derived measurements of myocardial performance and BNP blood levels (mean ± SD) in SSc patients with
normal or elevated PASP.
RV Tei-index LV Tei-index LV EF (%) BNP (pg/mL)
PASP ≤40mmHg (all patients, n = 69) 0.37 ±0.02 0.38 ±0.01 61 ± 93 3 ± 23
PASP >40mmHg (all patients, n = 37) 0.41 ±0.03 (P<. 001)
∗ 0.41 ±0.02 (P<. 001)
∗ 60 ± 5 163 ± 159 (P<. 0001)
∗
PASP >40mmHg (diﬀuse SSc, n = 21) 0.41 ±0.03 0.41 ±0.02 60 ± 5 167 ± 187
PASP >40mmHg (limited SSc, n = 16) 0.42 ±0.03 0.40 ±0.02 61 ± 4 164 ± 120
SSc: systemic sclerosis;
PASP: pulmonary artery systolic pressure;
BNP: B-type natriuretic peptide;
RV: right ventricular;
LV: left ventricular;
EF: ejection fraction.
∗Comparing to patients with PASP ≤40.
As shown in Table 3, age-adjusted partial correlation
coeﬃcients between individual TIMP-4 serum levels and the
corresponding levels of PASP revealed a positive signiﬁcant
correlation. Since multiple testing may result to false positive
associations,theBonferronicorrectionwasused,yieldingthe
same results. On the other hand, echocardiographic indica-
tors of either global myocardial performance (Tei-indices),
or of left ventricle’s systolic function (ejection fraction) did
not correlate signiﬁcantly with TIMP-4 circulating levels.
In contrast, increased left ventricle Tei-index, indicative
of impaired performance, was associated signiﬁcantly with
lower MMP-9 levels and MMP-9/TIMP-4 ratios (Table 3).
Finally, stepwise multivariate linear regression analy-
sis was performed to assess possible associations among
individual PASP measurements and the 3 corresponding
clinical and laboratory parameters under study for the 106
SSc patients. Using this model, we found that increased
PASP measurements were associated with TIMP-4 (log
transformed-continuous,β-coeﬃcient=0.180,P =.031)and
BNP (log transformed-continuous, β-coeﬃcient = 0.534,
P < .001). In contrast, no signiﬁcant associations could be
establishedwithage(continuous),MMP-9(continuous),SSc
type (diﬀuse, limited), or presence of lung ﬁbrosis (no, yes)
in our SSc patient cohort.
4. DISCUSSION
In the present study, we found that TIMP-4 serum levels are
increased in patients with either diﬀuse or limited SSc as
well as in patients with pulmonary ﬁbrosis. Because a rel-
atively large number of patients were available, appropriate
comparisons between patient subgroups were possible. No
signiﬁcant diﬀerences in TIMP-4 levels were noted between
diﬀuse or limited skin involvement, or between patients6 Mediators of Inﬂammation
with lung ﬁbrosis and those without, suggesting a not con-
vincing association of increased TIMP-4 serum levels with
the extent of ﬁbrosis characterizing SSc. However, further
analysis showed that increased TIMP-4 circulating levels
were higher in patients with elevated PASP measurements in
echocardiography, irrespective of skin involvement extent or
lungﬁbrosis.PASPwasconsideredelevatedwhenreachingor
exceeding the level of 40mmHg in echocardiography, as also
reported in other studies using noninvasive assessments of
pulmonary pressure [15, 17, 20]. Clearly, echocardiography
is not valid for the deﬁnite diagnosis of PH, but perform-
ing right cardiac catheterization in every patient was not
possible. However, similarly signiﬁcant associations between
elevated PASP and TIMP-4 levels were also obtained when
higher thresholds suggestive of PH, that is, 45mmHg [21,
22]o r5 0m mH g[ 18], were applied in our patient cohort.
Moreover, individual TIMP-4 levels correlated positively
with the corresponding PASP measurements in our 106
patients with SSc. Treatment with angiotensin-converting
enzyme inhibitors, known to inﬂuence TIMP-4 expression
[23, 24], appeared not to aﬀect this result. Age adjustment
was applied in statistical analyses because MMP-9 may
decrease [25], whereas TIMP-4 [25], BNP [26], PASP [17],
and echocardiographic indices of myocardial performance
[27]mayincreasewithage.Finally,despitethelimitationthat
serum measurements were performed only once, multivari-
ate linear regression analysis revealed signiﬁcant associations
of PASP elevations and increases of TIMP-4 serum levels,
but not with the presence of diﬀuse or limited SSc, or the
presence of lung ﬁbrosis in this cohort. In addition to TIMP-
4, PASP was associated with increased BNP blood levels, as
expected. Previous studies have shown that BNP levels are
directly related to the severity of PH in SSc [12], and may be
considered an independent predictor of PH in these patients
[28].
To the best of our knowledge, no previous studies have
examinedTIMP-4inpatientswithsystemicconnectivetissue
diseases or in patients with PH. Regarding TIMP-1 and
TIMP-2 serum levels, both have been found elevated in
SSc [29–34], and probably increased TIMP-2 levels correlate
with cardiopulmonary complications [32, 33]. In a larger
study examining both TIMP-1 and TIMP-2, only TIMP-1
levels were signiﬁcantly elevated in diﬀuse and limited SSc
compared to patients with primary Raynaud’s phenomenon
or controls, and no association with organ disease was found
[34].
On the other hand, MMP-9 levels were signiﬁcantly
raised only in our subgroup of patients with diﬀuse SSc,
in accordance with previous ﬁndings [35]. Overexpression
of TGF-beta in scleroderma skin [36, 37]m a yc o n t r i b u t e
to local MMP-9 induction and proteolytic activation [38],
thus resulting in increased circulating levels in patient with
extended skin sclerosis. Such increases explain perhaps the
trend toward signiﬁcance of the inverse correlation of MMP-
9 levels with DLCO and TLC measurements, since the
majority of our patients with pulmonary ﬁbrosis had diﬀuse
SSc.
Patients with elevated PASP appeared to have lower
MMP-9 mean levels, as also reported in SSc patients with
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Figure 2: Patients with SSc and elevated pulmonary artery systolic
pressure (PASP ≥ 40mmHg) have higher TIMP-4 levels and
smaller MMP-9/TIMP-4 ratios (bars show SD) than the remaining
patients (Mann-Whitney test).
PH[21].Sincebosentan[21]andiloprost[39]mayattenuate
MMP-9 expression, patients receiving such treatments were
excluded from our study. Those patients with elevated
PASP, most likely due to increased TIMP-4, had signiﬁcantly
smaller MMP-9/TIMP-4 ratios than the remaining patients,
suggesting that diﬀerent remodeling mechanisms of extra-
cellular matrix may operate. Since MMP-9/TIMP-4 ratio
reﬂects better the proteolytic activity, a decreased “net MMP
activity” may favor decreased degradation of extracellular
matrix components [40] within the cardiopulmonary vascu-
lature in these patients. As shown in an experimental model
of PH associated with marked inﬂammatory component
[41], therapeutic inhibition of MMP activity by TIMP-1
gene transfer aggravated PH, indicating that MMPs play a
protective role against pulmonary artery remodeling.
Moreover, lower individual MMP-9 levels and smaller
MMP-9/TIMP-4 ratios were associated with impaired left
ventricle myocardial performance, further implying a role
of TIMP-4/MMP-9 interactions in cardiopulmonary vascu-
lature abnormalities in SSc. Interestingly, cardiac remod-
eling in erythropoietin-transgenic mice, characterized by a
stiﬀer left ventricle with diastolic dysfunction, is associated
with decreased MMP-9 and increased TIMP-4 expression,
followed by a shift in collagen mRNA expression from type
III to type I [42]. It should be noted, however, that TIMPs
and MMPs play also a complex role in regulating angio-
genesis. For example, while TIMP-4 can induce apoptosis
in cardiac ﬁbroblasts [43], it may also act as an inhibitor of
capillary endothelial cell migration, but not of proliferation
or of angiogenesis in vivo [44]. On the other hand, mice
hyperexpressing the proﬁbrotic cytokine TGF-beta develop
myocardial ﬁbrosis and have a 2.5 increase of TIMP-4
myocardial expression compared to nontransgenic control
mice [45].Elias J. Gialafos et al. 7
5. CONCLUSION
The results presented herein may suggest that activation
of TIMP-4, perhaps by leading to enhanced interactions
with MMPs, plays a role in the increased stiﬀening within
the cardiopulmonary vasculature in SSc. Whether this
abnormality is a potential therapeutic target deserves further
investigation. As reported recently, TIMP-4 gene was iden-
tiﬁed as one of 8 candidate genes for SSc in a pilot study
using DNA pooling and genetic association analysis methods
[46]. Prospective studies to examine whether serum TIMP-4
measurements may be used to identify high-risk SSc patients
forcardiopulmonarycomplications,perhapsincombination
with other biomarkers [3, 47], are warranted.
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